drugset / Trial / NCT07413835
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Recruiting
6 enrolled
The Affiliated Hospital of Xuzhou Medical University
Shenzhen MagicRNA Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.
Timeline
- Start
- 2026-03-17
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HN2302 | Cell therapy | — | — |